2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. MAGL

MAGL

Monoacylglycerol lipase

MAGL

Related Products

PDF 0.44 MB

Monoacylglycerol lipase (MAGL) is a serine hydrolase that plays a crucial role catalysing the hydrolysis of monoglycerides into glycerol and fatty acids. MAGL links the endocannabinoid and eicosanoid systems together by degradation of the abundant endocannabinoid 2-arachidaoylglycerol into arachidonic acid, the precursor of prostaglandins and other inflammatory mediators.

MAGL plays a critical role in lipid signalling: i) it is the major enzyme that controls the levels of 2-AG, an important lipid with various neuroprotective effects; ii) inactivation of MAGL induces an elevation in brain levels of 2-AG and a reduction of AA, a key precursor of pro-inflammatory prostaglandins, resulting in the reduction of neuroinflammation; iii) MAGL regulates the levels of free fatty acids (FFAs) in aggressive cancer cells, and this MAGL-promoted fatty acid network drives a number of pro-tumorigenic signalling pathways. MAGL is emerging as a promising drug target for various diseases.

MAGL Related Products (72):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-12332
    JW 642
    		Inhibitor 99.90%
    JW 642 is a potent inhibitor of monoacylglycerol lipase (MAGL) that displays IC50 values of 7.6, 14, and 3.7 nM for inhibition of MAGL in mouse, rat, and human brain membranes, respectively.
    JW 642
  • HY-111538
    MAGL-IN-1
    		Inhibitor 99.78%
    MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC50 of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays.
    MAGL-IN-1
  • HY-120177
    KT182
    		Inhibitor 99.93%
    KT182 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC50 of 0.24 nM in Neuro2A cells.
    KT182
  • HY-119033
    MGL-IN-1
    		Inhibitor 98.65%
    MGL-IN-1 is a potent and selective irreversible MGL (β-lactam-based monoacylglycerol lipase) inhibitor. MGL-IN-1 alleviates symptoms in a MS model in vivo and exhibits analgesic effects in an acute inflammatory pain model in vivo. MGL-IN-1 displays high membrane permeability and brain penetrant.
    MGL-IN-1
  • HY-114926
    KT185
    		Inhibitor 99.30%
    KT185 is an orally-bioavailable, brain-penetrant and selective ABHD6 inhibitor, with an IC50 0.21 nM in Neuro2A cells.
    KT185
  • HY-121476
    Arachidonoyl Serinol
    		Inhibitor ≥98.0%
    Arachidonoyl Serinol, an endogenous cannabimimetic metabolite, is an inhibitor of monoacylglycerol lipase (MAGL). Arachidonoyl Serinol inhibits the hydrolysis of [3H]2-oleoylglycerol and [3H]anandamide with IC50s of ～70 μM.
    Arachidonoyl Serinol
  • HY-101457
    JZP-430
    		Inhibitor 99.74%
    JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC50 of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL).
    JZP-430
  • HY-111512
    PF-06795071
    		Inhibitor 99.31%
    PF-06795071 is a potent and selective covalent MAGL inhibitor with an IC50 of 3 nM.
    PF-06795071
  • HY-163733
    AKU-005
    		Inhibitor 99.48%
    AKU-005 is a FAAH and MAGL dual inhibitor with IC50 values of 63, 389 nM for rat and human FAAH, respectively. AKU-005 has the potential for the research of trigeminal hyperalgesia.
    AKU-005
  • HY-152148
    JZP-MA-11
    		Inhibitor 99.26%
    JZP-MA-11 is a positron emission tomography (PET) ligand targeting the endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. JZP-MA-11 selectively inhibits ABHD6 with an IC50 value of 126 nM. JZP-MA-11 can cross the blood-brain barrier (BBB). [18F]JZP-MA-11 has the potential for preclinical evaluation targeting the brain ABHD6 in mice and nonhuman primate (NHP).
    JZP-MA-11
  • HY-129121
    ML-​226
    		Inhibitor 98.76%
    ML226 is a potent α/β hydrolase domain-containing protein 11 (ABHD11) inhibitor in vitro and in situ with IC50s of 15 and 0.68 nM, respectively.
    ML-​226
  • HY-132310
    MAGL-IN-4
    		Inhibitor 99.91%
    MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain.
    MAGL-IN-4
  • HY-18544
    AA38-3
    		Inhibitor 99.89%
    AA38-3 is a serine hydrolase (SH) inhibitor. AA38-3 can inhibit three SHs, ABHD6, ABHD11, and FAAH.
    AA38-3
  • HY-121422
    JZP-361
    		Inhibitor 99.72%
    JZP-361 is a potent, reversible and selective inhibitor of human recombinant MAGL (hMAGL) with an IC50 of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research.
    JZP-361
  • HY-132246
    WWL123 analogue-1
    		Inhibitor 98.04%
    WWL123 analogue-1 is an analogue of WWL123. WWL123 is a potent and selective ABHD6 inhibitor with an IC50 of 430 nM. WWL123 crosses the blood-brain-barrier and inhibits ABHD6 in brain parenchyma. ABHD6 blockade by WWL123 exerts an antiepileptic effect in Pentylenetetrazole (PTZ)-induced epileptiform seizures and spontaneous seizures in R6/2 mice.
    WWL123 analogue-1
  • HY-136562
    N-Arachidonyl maleimide
    		Inhibitor 99.18%
    N-Arachidonyl maleimide is a potent, irreversible inhibitor of monoacylglycerol lipase (MAGL) with an IC50 value of 140 nM.
    N-Arachidonyl maleimide
  • HY-146342
    FAAH/MAGL-IN-3
    		Inhibitor
    FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC50 values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability.
    FAAH/MAGL-IN-3
  • HY-158339
    ABHD antagonist 2
    		Antagonist
    ABHD antagonist 2 (Compound 9) is an antagonist for alpha/beta-Hydrolase domain containing 6 (ABHD6), with IC50 <0.001 μM. ABHD antagonist 2 exhibits good binding ability with ABHD6, with IC50 of 0.002 μM.
    ABHD antagonist 2
  • HY-116212
    JCP-170
    		Inhibitor
    JCP-170, a substituted chloroisocoumarin, is an ABHD6 inhibitor. JCP-170 robustly and reproducibly inhibits metastatic seeding of the murine cell line 0688M and both human pancreatic ductal adenocarcinoma (PDAC) cell lines.
    JCP-170
  • HY-162315
    MAGL-IN-16
    		Inhibitor
    MAGL-IN-16 (compound 27) is an oral active, selective and reversible MAGL inhibitor with the IC50 value of 10.3 nM. MAGL-IN-16 can increase the level of 2-AG and shows antidepressant effect in mouse depressed model caused by chronic restraint stress.
    MAGL-IN-16